Spirair

Executive Summary

Spirair is a privately held, early-stage medical device company headquartered in San Francisco, California, founded in 2019. The company is focused on developing bioabsorbable implant technologies for ear, nose, and throat (ENT) procedures, specifically targeting nasal septal deviation and turbinate hypertrophy. Spirair aims to provide minimally invasive solutions that integrate seamlessly into existing ENT treatment algorithms, offering strong clinical outcomes and improved patient experiences. Unlike traditional surgical approaches, Spirair's implants are designed to be bioabsorbable, potentially reducing complications and recovery times. The company operates in the respiratory and medical device sectors and, as a private firm, has not disclosed its funding or valuation. With a novel product pipeline addressing common ENT conditions, Spirair is positioned to capture market share in the growing minimally invasive ENT space. However, the company faces regulatory hurdles and competition from established players, and its early-stage status implies significant execution risk. Overall, Spirair presents a compelling but speculative opportunity in the medtech landscape.

Upcoming Catalysts (preview)

• Q2 2027FDA 510(k) clearance for septal deviation implant60% success
• Q4 2026Positive topline results from pivotal clinical study50% success
• Q3 2026Strategic partnership or licensing deal with major ENT company40% success